Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: A report from the Children's Oncology Group

Blood

Volumn 111, Issue 6, 2008, Pages 3276-3285

  Fujii, Hisaki ^a   Cuvelier, Geoff ^a   She, Kevin ^a   Aslanian, Soudabeh ^a   Shimizu, Hiromi ^a   Kariminia, Amina ^a   Krailo, Mark ^b   Chen, Zhengjia ^c   McMaster, Rob ^a   Bergman, Axel ^a   Goldman, Frederick ^d   Grupp, Stephen A ^e   Wall, Donna A ^f   Gilman, Andrew L ^g   Schultz, Kirk R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f TEXAS TRANSPLANT INSTITUTE   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; CARDIOLIPIN ANTIBODY; CYCLOSPORIN A; CYTOKINE; DNA ANTIBODY; DOUBLE STRANDED DNA; HYDROXYCHLOROQUINE; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; MICROSOMAL AMINOPEPTIDASE; MITOCHONDRION ANTIBODY; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; PREDNISONE; RITUXIMAB; STEROID; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; BLOOD SAMPLING; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOUBLE BLIND PROCEDURE; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ADOLESCENT; ADULT; AUTOIMMUNE DISEASE; BLOOD; CHRONIC DISEASE; IMMUNOLOGY; INFANT; ONCOLOGY; PEDIATRICS; PRESCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INFANT; MALE; MEDICAL ONCOLOGY; PEDIATRICS; PROGNOSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; STEROIDS;

EID: 42449105346     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-08-106286     Document Type: Article

References (52)

1. Remberger M, Beelen DW, Fauser A, et al. Increased risk of extensive chronic graft-versushost disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood. 2005;105:548-551.
2. Kollman C, Howe CWS, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98: 2043-2051.
3. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versushost disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303-2314.
4. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062-2068.
5. Fraser C, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. 2006;108:2867-2873.
6. Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001;98:1695-1700.
7. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. N Engl J Med. 1999;341: 14-21.
8. Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, III: Biomarker Working Group Report. Biol Blood Marrow Transplant. 2006;12:126-137.
9. Pavletic SZ, Carter SL, Keman NA, et al. Influence of T-cell depletion on chronic graft-versushost disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood. 2005;106:3308-3313.
10. Schultz KR, Paquet J, Bader S, HayGlass KT Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant. 1995;16:289-295.
11. + T and B cells in transplants induce chronic graftversus-host disease with autoimmune manifestations. Blood. 2006;107:2993-3001.
12. Cutler C, Miklos D, Kim HT, etal. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108:756-762.
13. She K, Gilman AL, Aslanian S et al. Altered Tolllike receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus host disease. Biol Blood Marrow Transplant. 2007;13: 386-397.
14. New JY, Li B, Koh WP, et al. Tcell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant. 2002;29:979-986.
15. Hildebrandt GC, Duffner UA, Olkiewicz KM, et al. A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood. 2004;103:2417-2426.
16. Imamura M, Hashino S, Kobayashi H, et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant. 1994;13:745-751.
17. Okamoto H, Yamamura M, Morita Y, HaradaS, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 1997;40:1096-1105.
18. BanovicT, MacDonald KP, Morris ES, et al. TGF-β in allogeneic stem cell transplantation: friend or foe? Blood. 2005;106:2206-2214.
19. Theofilopoulos AN, Baccala R, BeutlerB, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23: 307-336.
20. Sarantopoulos S, Stevenson KE, Kim HT, et al. BAFF/Blys levels correlate with disease activity and alter peripheral B cell subsets in patients with chronic GVHD [abstract]. Blood. 2006;108:130. Abstract no. 41.
21. Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001; 166:6-10.
22. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44:1313-1319.
23. Foley R, Couban S, Walker I, et al. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation. Bone Marrow Transplant. 1998;21: 769-773.
24. Grimm J, Zeller W, Zander AR. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVH D. Bone Marrow Transplant. 1998;21:29-32.
25. Miyamoto T, Akashi K, Hayashi S, et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant. 1996;17:185-190.
26. Kobayashi S, Imamura M, Hashino S, Tanaka J, Asaka M. Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease. Leuk Lymphoma. 1997;28:159-169.
27. Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation. 1998;66: 863-871.
28. Campen DH, Horwitz DA, Quismorio FP Jr, Ehresmann GR, Martin WJ. Serum levels of IL-2 receptor and activity of rheumatic disease characterized by immune activation. Arthr Rheum. 1988;31:1358-1364.
29. Hinerfeld D, Innamorati D, Pirro J, Tam SW. Serum/plasma depletion with chicken immunoglobulin Y antibodies for proteomic analysis from multiple Mammalian species. J Biomol Tech. 2004; 15:184-190.
30. Biemann K, Scoble HA. Characterization by tandem mass spectrometry of structural modifications in proteins. Science. 1987;237:992-998.
31. Sutherland AP, Ng LG, Fletcher CA, et al. BAFF auguments certain Th1-associated inflammatory responses. J Immunol. 2005;174:5537-5544.
32. European Bioinformatics Institute, ftp://ftp.ebi. ac.uk/pub/databases/ MassSpecDB/. Accessed on August 21, 2006.
33. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics. 2006;5:573-588.
34. Tan EM, Qin H, Kennedy SH, Rouda S, Fox JW 4th, Moore JH Jr. Platelet-derived growth factors-AA and -BB regulate collagen and collagenase gene expression differentially in human fibroblasts. Biochem J. 1995;310:585-588.
35. Ludwicka A, Ohba T Trojanowska M, et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol. 1995;10:1876-1883.
36. Patriarca F, Skert C, Sperotto A, et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graftvs.-host disease and immune recovery. Exp Hematol. 2006;34:389-396.
37. Rouquette-Gally AM, Boyeldieu D, ProstAC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation: a study of 53 long-termsurviving patients. Transplantation. 1988;46:238-240.
38. Quaranta S, Shulman H, Ahmed A, et al. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin Immunol. 1999;91:106-116.
39. Wechalekar A, Cranfield T, Sinclair D, Ganzckowski M. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin Lab Haem. 2005;27:247-249.
40. Mackay F, Schuneider P, Rennert P, Browning J. BAFF and APRIL: a turorial on B cell survival. Annu Rev Immunol. 2003;21:231-264.
41. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, AkiraS, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med. 2005;202:321-331.
42. Pisitkun P, Deane JA. Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006; 312:1669-1672.
43. Luan Y, Xu W. The structure and main functions of aminopeptidase IN. Curr Med Chem. 2007;14: 639-647.
44. Soderberg C, Sumitran-Karuppan S, Ljungman P, Moller E. CD13-specific autoimmunity in cytomegalovirus-infected immunocompromised patients. Transplantation. 1996;61:594-600.
45. Larsen SL, Pedersen LO, Buus S, Stryhn A. T cell responses affected by aminopeptidase N (CD13)-mediated trimming of major histocompatibility complex class II-bound peptides. J Exp Med. 1996;184:183-189.
46. van Hensbergen Y, Broxterman HJ, Hanemaaijer R, et al. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res. 2002;8:3747-3754.
47. sSoderberg C, Larsson S, Rozell BL, Sumitran-Karuppan S, Ljungman P, Moller E. Cytomegalovirus-induced CD13-specific autoimmunity: a possible cause of chronic graft-vs-host disease. Transplantation. 1996;61:600-609.
48. Novobrantseva TI, Majeau GR, Amatucci A, et al. Attenuated liver fibrosis in the absence of B cells. J Clin Invest. 2005;115:3072-3082.
49. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymhpocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190:1697-1710.
50. Svegliati S, Olivieri A, Campelli N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood. 2007;110:237-241.
51. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol. 2006;24:467-496.
52. Farag SS. Chronic graft-versus-host disease: where do we go from here? Bone Marrow Transplant. 2004;33:569-577.